Developer docs
API playgroundTry for free, no card

Search company profiles

Biocytogen

Full company profile

uuid02marit

Namestring
Biocytogen
Legal namestring
百奥赛图(北京)医药科技股份有限公司
Websiteurl
bbctg.com.cn
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Biocytogen (百奥赛图) is a global biopharmaceutical company headquartered in Beijing, China, that operates an integrated drug discovery and preclinical research business centered on proprietary genetically engineered mouse platforms. The company was originally founded in Massachusetts, USA in 2008 with its Chinese entity established in 2009, and is dual-listed on the Shanghai STAR Market (688796.SH) and Hong Kong Stock Exchange (02315.HK), with founder Dr. Yuelei Shen serving as Chairman and CEO.

The company's core technology is its proprietary SUPCE (Size-Unlimited Precision Chromosome Engineering) gene editing platform, which enables large fragment in-situ replacement of antibody genes. SUPCE forms the foundation of the RenMice platform family, which includes RenMab for fully human monoclonal antibodies, RenLite for bispecific antibodies with common light chain technology, RenNano for fully human heavy-chain antibodies (nanobodies/VHH), and RenTCR mimic for targeting intracellular antigens through MHC-peptide complexes. These platforms support the company's "Thousand Antibodies Thousand Targets" (千鼠万抗) initiative, which has produced a library of 1M+ fully human antibody sequences against 1,000+ antigens. The company also operates the BioMice sub-brand for animal model and cell line sales, and provides preclinical pharmacology, PK/PD, and non-GLP toxicity services across oncology, autoimmune/inflammatory, metabolic, neuroscience, cardiovascular, and ophthalmology disease areas.

Biocytogen monetizes through four primary revenue streams: (1) preclinical CRO services including pharmacology and efficacy studies; (2) platform licensing of RenMice platforms to pharmaceutical partners; (3) drug co-development and asset transfer through upfront payments, milestones, and royalties; and (4) animal model sales. The company serves 200+ pharmaceutical and biotechnology customers globally, including Merck (Germany), BeiGene, Innovent Biologics, Xencor, Alexion Pharmaceuticals, and others, and has signed 350+ cumulative drug co-development/licensing agreements as of December 2025. Operations span Beijing (headquarters), Shanghai, and Haimen in China; Waltham (37,000 sq ft R&D facility), South San Francisco, and San Diego in the US; and Heidelberg (Biocytogen Europe Innovation Center) in Germany, with animal model sales reaching 20+ countries.

Short descriptiontext

Biocytogen (百奥赛图) is a Beijing-headquartered, dual-listed biotech (Shanghai STAR and HKEX) that develops proprietary RenMice humanized antibody discovery platforms powered by SUPCE gene editing technology, provides preclinical CRO services, and licenses/co-develops antibody assets with global pharmaceutical and biotechnology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery platforms, preclinical CRO services, humanized mouse models, gene editing services, bispecific antibody development
Industry5 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical CRO Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Preclinical CRO Services
TypeProfessional Services
Description

Provides preclinical pharmacology and efficacy services, gene editing services, and animal model provision to pharmaceutical and biotech companies globally. Services include in vivo pharmacology, in vitro pharmacology, PK/PD studies, and non-GLP toxicity studies.

biocytogen.com.cn
2Platform Licensing
TypeLicensing Royalties
Description

Licenses proprietary RenMice platforms (RenMab, RenLite, RenNano, RenTCR, RenTCR mimic) to pharmaceutical and biotech companies for antibody discovery. Generates licensing fees and milestone payments.

biocytogen.com.cn
3Drug Co-development and Asset Transfer
TypeLicensing Royalties
Description

Co-develops and out-licenses antibody drug candidates discovered through the 'Thousand Antibodies Thousand Targets' program. Generates upfront payments, milestone payments, and royalties on product sales.

biocytogen.com.cn
4Animal Model Sales
TypeOne Time License
Description

Sells genetically engineered animal models including humanized mice, immunodeficient models, and disease models to research institutions and pharmaceutical companies.

biocytogen.com.cn
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1百奥动物 (BioMice)
Description

Sub-brand for genetically engineered animal and cell models, offering thousands of ready-made drug target humanized animal/cell models for preclinical efficacy, safety evaluation, and mechanism research.

biocytogen.com.cn
Core offering1 text field

Biocytogen develops proprietary RenMice antibody discovery platforms (RenMab, RenLite, RenNano, RenTCR mimic) built on its SUPCE gene editing technology for generating fully human monoclonal, bispecific, heavy-chain, and TCR-mimic antibodies. The company also produces and sells genetically engineered animal and cell line models, provides custom gene editing services, and conducts preclinical pharmacology, PK/PD, and efficacy/toxicity studies for global pharmaceutical and biotechnology partners. Its Thousand Mouse Thousand Antibody program has produced over 1 million fully human antibody sequences across more than 1,000 targets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 8,600+ drug evaluation projects completed
+6 more records
Product overview1 text field

Biocytogen is a global innovation-driven biopharmaceutical company that has developed a comprehensive drug discovery ecosystem centered on its proprietary RenMice® fully human antibody platforms. The core product portfolio includes five integrated platforms: RenMab® for monoclonal antibodies, RenLite® for bispecific antibodies, RenNano® for heavy chain antibodies (nanobodies), RenTCR mimic™ for intracellular antigens, and a GPCR antibody platform. These platforms are powered by the company's proprietary SUPCE™ gene editing technology and support the large-scale 'Thousand Mouse Thousand Antibody' initiative. Biocytogen also provides preclinical services including gene editing services, animal models and cell lines (BioMice sub-brand), pharmacology and efficacy studies, and PK/PD analysis. The company operates disease-specific solutions across oncology, autoimmune/inflammatory diseases, metabolic disorders, neuroscience, cardiovascular/cerebrovascular conditions, and ophthalmology. As of December 2025, Biocytogen has signed over 350 drug co-development/licensing agreements globally.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Merck (Germany)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-09-01
Description

Licensed RenMice platform for antibody discovery and preclinical antibody drug co-development through the Thousand Antibodies Thousand Targets program.

biocytogen.com.cn
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed RenMice platform for therapeutic antibody development.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed RenMice platform for antibody drug discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership using RenMice platform for bispecific antibody development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Preclinical antibody drug co-development and licensing partnership. Joint advancement of clinical stage antibody drug molecules.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint advancement of preclinical and clinical stage antibody drug molecules.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint advancement of preclinical and clinical stage antibody drug molecules.

8Huarun Biology
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Preclinical antibody drug co-development through Thousand Antibodies Thousand Targets program.

biocytogen.com.cn
9Nanjing Tianqing
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Preclinical antibody drug co-development through Thousand Antibodies Thousand Targets program.

biocytogen.com.cn
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Preclinical antibody drug co-development for Japanese market.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration in Genomic Medicine Preclinical Pharmacology for novel therapeutic development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Development of five B-NDG hIL6 models including Fabre, MPS-IV, Niemann Pick A/B, Hemophilia B, and Hypophosphatasia programs.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AbCellera operates a leading antibody discovery platform using single-cell microfluidic screening, partnering with pharma to discover fully human therapeutic antibodies — directly comparable to Biocytogen's RenMice-based platform licensing model.

TypeDirect peer
Description

Regeneron's VelocImmune humanized mouse platform is the closest analog to Biocytogen's RenMice — both generate fully human antibodies from genetically engineered mice and license them to pharma partners globally.

TypeDirect peer
Description

GenScript is a China-headquartered life sciences services and cell therapy company offering gene synthesis, protein/antibody services, preclinical animal models and CRO services — direct overlap with Biocytogen's gene editing, animal models and preclinical CRO business.

TypeBroad incumbent
Description

WuXi Biologics is a much larger China-based biologics CRO/CDMO offering end-to-end antibody discovery, development and manufacturing — broader scope but overlapping target customers and comparable fully human antibody discovery services to Biocytogen's RenMice platforms.

TypeBroad incumbent
Description

Pharmaron is a China-founded global CRO/CDMO offering preclinical pharmacology, animal models and biologics services — comparable to Biocytogen's preclinical CRO services arm across oncology, autoimmune and metabolic disease models.

TypeBroad incumbent
Description

Charles River is a leading global preclinical CRO providing animal models, in vivo pharmacology and safety assessment services — overlapping with Biocytogen's preclinical pharmacology and animal model sales business.

TypeDirect peer
Description

Cyagen is a China-based gene editing and humanized mouse model provider with comparable offerings in custom KO/KI mice and preclinical research models — direct competition to Biocytogen's gene editing services and animal model catalog.

TypeDirect peer
Description

Taconic is a global supplier of genetically engineered mouse models and related preclinical research services — comparable to Biocytogen's BioMice animal model portfolio and gene-humanized model offerings.

9Harbour BioMed
TypeEmerging player
Description

Harbour BioMed operates the H2L2 and HCAb transgenic mouse platforms for fully human antibody discovery and out-licenses assets to global pharma — emerging peer with overlapping platform licensing model and therapeutic antibody pipeline.

TypeEmerging player
Description

Crown Bioscience (JSR Life Sciences) provides preclinical oncology and immuno-oncology CRO services including humanized mouse models and in vivo pharmacology — comparable to Biocytogen's oncology preclinical solutions and humanized mouse offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocytogen

Biopharmaceutical CRO Servicesbbctg.com.cn

Biocytogen (百奥赛图) is a Beijing-headquartered, dual-listed biotech (Shanghai STAR and HKEX) that develops proprietary RenMice humanized antibody discovery platforms powered by SUPCE gene editing technology, provides preclinical CRO services, and licenses/co-develops antibody assets with global pharmaceutical and biotechnology companies.

What Biocytogen does

Biocytogen (百奥赛图) is a global biopharmaceutical company headquartered in Beijing, China, that operates an integrated drug discovery and preclinical research business centered on proprietary genetically engineered mouse platforms. The company was originally founded in Massachusetts, USA in 2008 with its Chinese entity established in 2009, and is dual-listed on the Shanghai STAR Market (688796.SH) and Hong Kong Stock Exchange (02315.HK), with founder Dr. Yuelei Shen serving as Chairman and CEO.

The company's core technology is its proprietary SUPCE (Size-Unlimited Precision Chromosome Engineering) gene editing platform, which enables large fragment in-situ replacement of antibody genes. SUPCE forms the foundation of the RenMice platform family, which includes RenMab for fully human monoclonal antibodies, RenLite for bispecific antibodies with common light chain technology, RenNano for fully human heavy-chain antibodies (nanobodies/VHH), and RenTCR mimic for targeting intracellular antigens through MHC-peptide complexes. These platforms support the company's "Thousand Antibodies Thousand Targets" (千鼠万抗) initiative, which has produced a library of 1M+ fully human antibody sequences against 1,000+ antigens. The company also operates the BioMice sub-brand for animal model and cell line sales, and provides preclinical pharmacology, PK/PD, and non-GLP toxicity services across oncology, autoimmune/inflammatory, metabolic, neuroscience, cardiovascular, and ophthalmology disease areas.

Biocytogen monetizes through four primary revenue streams: (1) preclinical CRO services including pharmacology and efficacy studies; (2) platform licensing of RenMice platforms to pharmaceutical partners; (3) drug co-development and asset transfer through upfront payments, milestones, and royalties; and (4) animal model sales. The company serves 200+ pharmaceutical and biotechnology customers globally, including Merck (Germany), BeiGene, Innovent Biologics, Xencor, Alexion Pharmaceuticals, and others, and has signed 350+ cumulative drug co-development/licensing agreements as of December 2025. Operations span Beijing (headquarters), Shanghai, and Haimen in China; Waltham (37,000 sq ft R&D facility), South San Francisco, and San Diego in the US; and Heidelberg (Biocytogen Europe Innovation Center) in Germany, with animal model sales reaching 20+ countries.

Biocytogen firmographics

Firmographics
Name
Biocytogen
Legal name
百奥赛图(北京)医药科技股份有限公司
Website
https://bbctg.com.cn
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
Biocytogen (百奥赛图) is a Beijing-headquartered, dual-listed biotech (Shanghai STAR and HKEX) that develops proprietary RenMice humanized antibody discovery platforms powered by SUPCE gene editing technology, provides preclinical CRO services, and licenses/co-develops antibody assets with global pharmaceutical and biotechnology companies.
Ownership category
akta.pro rank

Biocytogen industry classification

Industry
Product category
Biopharmaceutical CRO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Antibody discovery platforms
  • Preclinical CRO services
  • Humanized mouse models
  • Gene editing services
  • Bispecific antibody development

Where Biocytogen is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices7 records

Markets served

Biocytogen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Preclinical CRO Services: Provides preclinical pharmacology and efficacy services, gene editing services, and animal model provision to pharmaceutical and biotech companies globally. Services include in vivo pharmacology, in vitro pharmacology, PK/PD studies, and non-GLP toxicity studies.
  2. Platform Licensing: Licenses proprietary RenMice platforms (RenMab, RenLite, RenNano, RenTCR, RenTCR mimic) to pharmaceutical and biotech companies for antibody discovery. Generates licensing fees and milestone payments.
  3. Drug Co-development and Asset Transfer: Co-develops and out-licenses antibody drug candidates discovered through the 'Thousand Antibodies Thousand Targets' program. Generates upfront payments, milestone payments, and royalties on product sales.
  4. Animal Model Sales: Sells genetically engineered animal models including humanized mice, immunodeficient models, and disease models to research institutions and pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Biocytogen product offering

Product offering

Core offering

Biocytogen develops proprietary RenMice antibody discovery platforms (RenMab, RenLite, RenNano, RenTCR mimic) built on its SUPCE gene editing technology for generating fully human monoclonal, bispecific, heavy-chain, and TCR-mimic antibodies. The company also produces and sells genetically engineered animal and cell line models, provides custom gene editing services, and conducts preclinical pharmacology, PK/PD, and efficacy/toxicity studies for global pharmaceutical and biotechnology partners. Its Thousand Mouse Thousand Antibody program has produced over 1 million fully human antibody sequences across more than 1,000 targets.

Product overview

Biocytogen is a global innovation-driven biopharmaceutical company that has developed a comprehensive drug discovery ecosystem centered on its proprietary RenMice® fully human antibody platforms. The core product portfolio includes five integrated platforms: RenMab® for monoclonal antibodies, RenLite® for bispecific antibodies, RenNano® for heavy chain antibodies (nanobodies), RenTCR mimic™ for intracellular antigens, and a GPCR antibody platform. These platforms are powered by the company's proprietary SUPCE™ gene editing technology and support the large-scale 'Thousand Mouse Thousand Antibody' initiative. Biocytogen also provides preclinical services including gene editing services, animal models and cell lines (BioMice sub-brand), pharmacology and efficacy studies, and PK/PD analysis. The company operates disease-specific solutions across oncology, autoimmune/inflammatory diseases, metabolic disorders, neuroscience, cardiovascular/cerebrovascular conditions, and ophthalmology. As of December 2025, Biocytogen has signed over 350 drug co-development/licensing agreements globally.

Differentiator

Problem solved

Functional benefit

Brands

  • 百奥动物 (BioMice): Sub-brand for genetically engineered animal and cell models, offering thousands of ready-made drug target humanized animal/cell models for preclinical efficacy, safety evaluation, and mechanism research.

Quantifiable outcome

  • 8,600+ drug evaluation projects completed
  • +6 more outcomes

Companies that use Biocytogen

Customer profile

Named customers13 records

Segments3 records

Ideal customer profiles3 records

Biocytogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Biocytogen partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and major.

  • Merck (Germany)coreOEM/ Whitelabel/ Licensing Partner · 1 September 2022Licensed RenMice platform for antibody discovery and preclinical antibody drug co-development through the Thousand Antibodies Thousand Targets program.
  • BeiGenecoreOEM/ Whitelabel/ Licensing PartnerLicensed RenMice platform for therapeutic antibody development.
  • Innovent BiologicscoreOEM/ Whitelabel/ Licensing PartnerLicensed RenMice platform for antibody drug discovery.
  • XencorcoreStrategic or Co-development PartnerStrategic partnership using RenMice platform for bispecific antibody development.
  • Rongchang BiologycoreStrategic or Co-development PartnerPreclinical antibody drug co-development and licensing partnership. Joint advancement of clinical stage antibody drug molecules.
  • TRACON PharmaceuticalscoreStrategic or Co-development PartnerJoint advancement of preclinical and clinical stage antibody drug molecules.
  • Qidai PharmaceuticalscoreStrategic or Co-development PartnerJoint advancement of preclinical and clinical stage antibody drug molecules.
  • Huarun BiologymajorStrategic or Co-development PartnerPreclinical antibody drug co-development through Thousand Antibodies Thousand Targets program.
  • Nanjing TianqingmajorStrategic or Co-development PartnerPreclinical antibody drug co-development through Thousand Antibodies Thousand Targets program.
  • LiberoThera (Japan)majorStrategic or Co-development PartnerPreclinical antibody drug co-development for Japanese market.
  • Alexion PharmaceuticalsmajorStrategic or Co-development PartnerCollaboration in Genomic Medicine Preclinical Pharmacology for novel therapeutic development.
  • Be BiopharmamajorStrategic or Co-development PartnerDevelopment of five B-NDG hIL6 models including Fabre, MPS-IV, Niemann Pick A/B, Hemophilia B, and Hypophosphatasia programs.

Scale indicators13 records

Recent moves12 records

Expansion highlights6 records

Biocytogen competitors and assessment

Company assessment

Direct peers

  • AbCellera Biologics: AbCellera operates a leading antibody discovery platform using single-cell microfluidic screening, partnering with pharma to discover fully human therapeutic antibodies — directly comparable to Biocytogen's RenMice-based platform licensing model.
  • Regeneron Pharmaceuticals: Regeneron's VelocImmune humanized mouse platform is the closest analog to Biocytogen's RenMice — both generate fully human antibodies from genetically engineered mice and license them to pharma partners globally.
  • GenScript Biotech: GenScript is a China-headquartered life sciences services and cell therapy company offering gene synthesis, protein/antibody services, preclinical animal models and CRO services — direct overlap with Biocytogen's gene editing, animal models and preclinical CRO business.
  • Cyagen Biosciences: Cyagen is a China-based gene editing and humanized mouse model provider with comparable offerings in custom KO/KI mice and preclinical research models — direct competition to Biocytogen's gene editing services and animal model catalog.
  • Taconic Biosciences: Taconic is a global supplier of genetically engineered mouse models and related preclinical research services — comparable to Biocytogen's BioMice animal model portfolio and gene-humanized model offerings.

Broad incumbents

  • WuXi Biologics: WuXi Biologics is a much larger China-based biologics CRO/CDMO offering end-to-end antibody discovery, development and manufacturing — broader scope but overlapping target customers and comparable fully human antibody discovery services to Biocytogen's RenMice platforms.
  • Pharmaron: Pharmaron is a China-founded global CRO/CDMO offering preclinical pharmacology, animal models and biologics services — comparable to Biocytogen's preclinical CRO services arm across oncology, autoimmune and metabolic disease models.
  • Charles River Laboratories: Charles River is a leading global preclinical CRO providing animal models, in vivo pharmacology and safety assessment services — overlapping with Biocytogen's preclinical pharmacology and animal model sales business.

Emerging players

  • Harbour BioMed: Harbour BioMed operates the H2L2 and HCAb transgenic mouse platforms for fully human antibody discovery and out-licenses assets to global pharma — emerging peer with overlapping platform licensing model and therapeutic antibody pipeline.
  • Crown Bioscience: Crown Bioscience (JSR Life Sciences) provides preclinical oncology and immuno-oncology CRO services including humanized mouse models and in vivo pharmacology — comparable to Biocytogen's oncology preclinical solutions and humanized mouse offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Biocytogen compliance and trust

Trust signal

Compliance1 record

Biocytogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocytogen leadership team

Management profile

Number of profiles

Profiles1 record

Biocytogen subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Biocytogen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocytogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocytogen

What does Biocytogen do?

Biocytogen develops proprietary RenMice antibody discovery platforms (RenMab, RenLite, RenNano, RenTCR mimic) built on its SUPCE gene editing technology for generating fully human monoclonal, bispecific, heavy-chain, and TCR-mimic antibodies. The company also produces and sells genetically engineered animal and cell line models, provides custom gene editing services, and conducts preclinical pharmacology, PK/PD, and efficacy/toxicity studies for global pharmaceutical and biotechnology partners. Its Thousand Mouse Thousand Antibody program has produced over 1 million fully human antibody sequences across more than 1,000 targets.

Is Biocytogen a public or private company?

Biocytogen is a public company. It is classified as public and is currently operating.

When was Biocytogen founded?

Biocytogen was founded in 2009. It employs 51 to 100 people.

Where is Biocytogen based?

Biocytogen is headquartered in Beijing, China, in the Asia region.

How does Biocytogen make money?

Four revenue lines are on record. Preclinical CRO Services are the primary driver. The others are platform Licensing, drug Co-development and Asset Transfer and animal Model Sales.

Who are Biocytogen's main competitors?

Direct peers on record are AbCellera Biologics, Regeneron Pharmaceuticals, GenScript Biotech, Cyagen Biosciences and Taconic Biosciences. Broad incumbents are WuXi Biologics, Pharmaron and Charles River Laboratories. Emerging players are Harbour BioMed and Crown Bioscience.

Does Biocytogen have an API?

No public API is recorded for Biocytogen.

What industry is Biocytogen in?

Biocytogen's product category is Biopharmaceutical CRO Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales